Cell Line Data Sheet for SJ-GBM2

Disease:	Glioblastoma multiforme
Phase of Therapy:	Post-Chemotherapy (Progressive Disease)
Treatment:	N/A
Disease Stage:	N/A
Gender:	Female
Age at diagnosis:	50 months
Race:	Caucasian
Age at sample collection:	N/A
Source of Culture:	Solid tumor
Primary Tumor Site:	Brain
Date Established:	N/A
MYCN Patient:	N/A
MYCN Cell line:	Relative copy number - NA
TH mRNA:	N/A
p53 functionality:	Non-functional
Telomere Mechanism:	N/A
ALK:	N/A
RNAseq:	N/A
WES:	N/A

Growth Conditions:	Please see Protocols section at https://www.cccells.org/protocols.php 5% CO_2, 20% O_2, 37.0°C
Media Formulation:	Please see Protocols section at https://www.cccells.org/protocols.php Cells are grown in a base medium of Iscove's Modified Dulbecco's Medium plus the following supplements (to a final concentration): 20% Fetal Bovine Serum, 4mM L-Glutamine, 1X ITS (5 µg/mL insulin, 5 µg/mL transferrin, 5 ng/mL selenous acid)
Doubling Time:	N/A
Growth Properties:	Adherent
STR Profile:	May be obtained at https://strdb.cccells.org/
Notes:	None

All cell lines are antibiotic-free, mycoplasma-free, and cryopreserved in 50% FBS / 7.5% DMSO. Each vial label contains the cell line name, passage number, total viable cell count (usually 5-10e6), the overall cell viability, and date frozen. All cell lines are validated with original patient sample by STR analysis.

Cell Line Data Sheet for SJ-GBM2

Cell Line Name: **SJ-GBM2**

References:

1. Kang MH, Smith MA, Morton CL, Keshlava N, Houghton PJ, Reynolds CP. National Cancer Institute Pediatric Preclinical Testing Program: Model Description for In Vitro Cytotoxicity Testing. *Pediatr Blood Cancer*. 56: 239-249, 2011. PubMed ID: 20922763(www.PPTPinvitro.org)
   See NCI Pediatric Preclinical Testing Program references (29-58).

Cell Line Data Sheet for SJ-GBM2

Cell Line Name: **SJ-GBM2**

Low confluency (10x magnification)

High confluency (10x magnification)

Low confluency (20x magnification)

High confluency (20x magnification)